Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

Phase 1 Completed 30 enrolled Novartis

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients

Timeline

Start: 2008-07
Primary completion: 2009-07
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Albinterferon Alfa-2b	Protein / enzyme biologic	—	Subcutaneous

Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

Summary

Timeline

Drugs

Indications